HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Haixun Guo Selected Research

alpha-MSH

4/2013Melanoma targeting property of a Lu-177-labeled lactam bridge-cyclized alpha-MSH peptide.
4/2013Design and evaluation of new Tc-99m-labeled lactam bridge-cyclized alpha-MSH peptides for melanoma imaging.
6/2012Gallium-67-labeled lactam bridge-cyclized alpha-MSH peptides with enhanced melanoma uptake and reduced renal uptake.
4/2011Effects of the amino acid linkers on the melanoma-targeting and pharmacokinetic properties of 111In-labeled lactam bridge-cyclized alpha-MSH peptides.
11/2010Technetium-99m-labeled Arg-Gly-Asp-conjugated alpha-melanocyte stimulating hormone hybrid peptides for human melanoma imaging.
9/2010Replacement of the Lys linker with an Arg linker resulting in improved melanoma uptake and reduced renal uptake of Tc-99m-labeled Arg-Gly-Asp-conjugated alpha-melanocyte stimulating hormone hybrid peptide.
3/2010Reduction of the ring size of radiolabeled lactam bridge-cyclized alpha-MSH peptide, resulting in enhanced melanoma uptake.
12/2009Gallium-67-labeled lactam bridge-cyclized alpha-melanocyte stimulating hormone peptide for primary and metastatic melanoma imaging.
11/2009Effect of DOTA position on melanoma targeting and pharmacokinetic properties of 111In-labeled lactam bridge-cyclized alpha-melanocyte stimulating hormone peptide.
4/2009Metastatic melanoma imaging with an (111)In-labeled lactam bridge-cyclized alpha-melanocyte-stimulating hormone peptide.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Haixun Guo Research Topics

Disease

15Melanoma (Melanoma, Malignant)
10/2020 - 02/2008
7Neoplasms (Cancer)
01/2022 - 02/2008
2Infections
06/2010 - 10/2008
1Pancreatic Neoplasms (Pancreatic Cancer)
01/2022
1Adenocarcinoma
01/2022
1Lymphoma (Lymphomas)
01/2022
1Colonic Neoplasms (Colon Cancer)
04/2015
1Colitis
03/2014
1Prostatic Neoplasms (Prostate Cancer)
09/2011
1Breast Neoplasms (Breast Cancer)
08/2011

Drug/Important Bio-Agent (IBA)

16Peptides (Polypeptides)IBA
12/2014 - 02/2008
11LactamsIBA
12/2014 - 02/2008
11alpha-MSHIBA
04/2013 - 02/2008
9Type 1 Melanocortin ReceptorIBA
12/2014 - 08/2009
71,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA
08/2012 - 04/2009
6Melanocyte-Stimulating Hormones (MSH)IBA
12/2014 - 08/2009
5AcidsIBA
12/2014 - 04/2011
5N-glycylglutamic acidIBA
06/2012 - 02/2008
3Amino AcidsFDA Link
12/2014 - 08/2009
3arginylprolineIBA
06/2012 - 04/2009
3lysinenorleucineIBA
06/2012 - 04/2009
3arginyl-glycyl-aspartic acidIBA
11/2010 - 08/2009
2Biological ProductsIBA
04/2015 - 06/2010
2triazacyclononaneIBA
08/2012 - 06/2012
21,4,7- triazacyclononane- N,N',N''- triacetic acid (NOTA)IBA
08/2012 - 06/2012
2tryptophylglycineIBA
06/2012 - 11/2009
2Gonadotropin-Releasing Hormone (GnRH)FDA Link
09/2011 - 08/2011
2ciprofloxacin dithiocarbamateIBA
06/2010 - 10/2008
1Ethanol (Ethyl Alcohol)IBA
01/2022
1GlucansIBA
01/2022
1NF-kappa B (NF-kB)IBA
10/2021
1Immune Checkpoint InhibitorsIBA
10/2020
1Immunoglobulin FragmentsIBA
10/2020
1Biomarkers (Surrogate Marker)IBA
10/2020
1sphingosine 1-phosphate (sphingosine-1-phosphate)IBA
04/2015
1omega-aminocaprylic acidIBA
12/2014
1EDDA (NiEDDA)IBA
12/2014
1HydrocarbonsIBA
12/2014
1Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric
12/2014
1Dextran SulfateIBA
03/2014
1Methotrexate (Mexate)FDA LinkGeneric
03/2014
1Pharmaceutical PreparationsIBA
03/2014
1Therapeutic UsesIBA
03/2014
1Chelating AgentsIBA
04/2013
1LHRH Receptors (Gonadotropin-Releasing Hormone Receptor)IBA
08/2011
1Radioisotopes (Radionuclides)IBA
04/2011
1Ac- Cys- Cys- Glu- His- D- Phe- Arg- Trp- Cys- Lys- Pro- Val- NH2IBA
11/2010
1IntegrinsIBA
11/2010
1Deoxyglucose (2 Deoxy D glucose)IBA
04/2009
1ACTH (7-10)IBA
04/2009

Therapy/Procedure

5Therapeutics
10/2020 - 08/2009
1Immunotherapy
01/2022